ImmuCell CorporationICCCNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P29
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-100.00%
2024107.66%
2023-202.76%
2022-261.80%
2021-27.47%
2020463.39%
2019162.54%
2018-131.76%
2017463.02%
2016-111.17%